trending Market Intelligence /marketintelligence/en/news-insights/trending/IuVBsqWY7cAhaiOinKu-bQ2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

NephroGenex, Medpace enter restructuring agreement


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

NephroGenex, Medpace enter restructuring agreement

NephroGenex Inc. entered into an agreement with Medpace Inc. in connection with its restructuring.

The restructuring will be implemented through a Chapter 11 plan of reorganization, subject to the approval of the bankruptcy court.

Under the agreement, Medspace will waive its cash distribution with respect to its asserted $4.3 million unsecured claim against NephroGenex in exchange for 100% of the newly issued common stock in the reorganized company.

NephroGenex previously filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code to the U.S. Bankruptcy Court for the District of Delaware on April 30, 2016.

Kurtzman Carson Consultants LLC is acting as the company's claims agent for the reorganization process.